Evaluation of Angiotensin II in Patients With Catecholamine-Resistant Vasodilatory Shock Requiring Continuous Renal Replacement Therapy (ANGEL CRRT)
Main finding · ICU mortalityResult — go to the resultAdjusted odds ratio 0.438 95% CI 0.239–0.805Authors' conclusion
ANGII was associated with lower mortality in patients who received renal replacement therapy compared to SOC.
Study context
- Population
- Critically ill adults with catecholamine-resistant vasodilatory shock (norepinephrine or equivalent ≥0.5 mcg/kg/min) receiving CRRT
- Participants
- 265 adults
- Exposure
- Adjunctive angiotensin II vs standard-of-care (SOC) vasopressors alone
- Angiotensin II (ANGII)n = 70
- SOCn = 195reference
- Outcome
- ICU mortality
Methodological detailsmulticentre, single health system
- Multicentre
- Single health system
Main finding
As reported in the abstract
Adjusted odds ratio
0.438
95% CI 0.239–0.805
P = 0.008
By group
ANGII vs SOC
aOR 0.438 (95% CI 0.239–0.805); P = 0.008
Observational data: associations, not effects.
Secondary outcomes
| Outcome | ANGII | SOC | aOR (95% CI) | P value | |
|---|---|---|---|---|---|
| 30-day mortality | 67.1% | 78.5% | 0.479 (0.256–0.898) | P = 0.022 | |
| 0.20.5125Adjusted odds ratio (log scale) |
Time to shock reversal and Sequential Organ Failure Assessment (SOFA) score at 72 hours
- Differences not statistically significant
Safety
Fungal infections
P = 0.016
- Fungal infections: other adverse effects evaluated not statistically significant
Original publication
Evaluation of Angiotensin II in Patients With Catecholamine-Resistant Vasodilatory Shock Requiring Continuous Renal Replacement Therapy (ANGEL CRRT). J Cardiothorac Vasc Anesth. Published 31 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →